Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21554977 | 0.87 | CTSL (0.46) | CTSLFKBP1APDK1PDK2PDK3 | |
| SCHEMBL21555068 | 0.87 | CTSL (0.46) | CTSLFKBP1APDK1PDK2PDK3 | |
| SCHEMBL21159514 | 0.87 | CTSL (0.46) | CTSLFKBP1APDK1PDK2PDK3 | |
| SCHEMBL8279010 | 0.85 | CTSL (0.49) | CTSLFKBP1APDK1PDK2PDK3 | |
| SCHEMBL20539082 | 0.84 | CTSL (0.46) | CTSLFKBP1APDK1PDK2PDK3 | |
| SCHEMBL18591209 | 0.84 | CTSL (0.46) | CTSLFKBP1APDK1PDK2PDK3 | |
| SCHEMBL18591210 | 0.84 | CTSL (0.46) | CTSLFKBP1APDK1PDK2PDK3 | |
| SCHEMBL21554728 | 0.84 | CTSL (0.46) | CTSLFKBP1APDK1PDK2PDK3 | |
| SCHEMBL30272160 | 0.84 | CTSL (0.46) | CTSLFKBP1APDK1PDK2PDK3 | |
| SCHEMBL20146333 | 0.83 | PDK1 (0.50) | CTSLFKBP1APDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CTSL 203/4885FKBP1A 3159/4885PDK1 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.